Public market insider buying at Fennec Pharmaceuticals (T:FRX)

Rostislav Christov Raykov, CEO and Director, acquired 29,167 Common Shares on a direct ownership basis at a price of $15.100 on April 1st, 2024. This represents a $440,422 investment into the company's shares and an account share holdings change of 1.2%.

Robert Christopher Andrade, CFO, acquired 12,500 Common Shares on a direct ownership basis at the same price. This represents a $188,750 investment into the company's shares and an account share holdings change of 8.4%.

Fennec Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.